Coinfection
CROI 2013: Adding Telaprevir Increases Acute Hepatitis C Cure Rate for HIV+ Men
- Details
- Category: HIV/Hepatitis Coinfection
- Published on Tuesday, 12 March 2013 00:00
- Written by Liz Highleyman
Adding telaprevir (Incivek) to pegylated interferon and ribavirin shortens the duration of therapy and improves the likelihood of a cure for HIV positive men with acute sexually transmitted hepatitis C virus (HCV), according to study findings presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
CROI 2013: Simeprevir and Faldaprevir Boost Interferon Response Rates for HIV/HCV Coinfected
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 11 March 2013 00:00
- Written by Liz Highleyman
Adding the hepatitis C virus (HCV) protease inhibitors simeprevir or faldaprevir to pegylated interferon plus ribavirin produces higher response rates and the potential for shorter treatment for HIV/HCV coinfected people, according to 2 studies presented last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: Retrovirus Conference Starts Sunday in Atlanta
- Details
- Category: HIV Treatment
- Published on Thursday, 28 February 2013 00:00
- Written by Liz Highleyman
The 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) kicks off Sunday, March 3, at the Georgia World Congress Center in Atlanta. HIVandHepatitis.com will be on site next week to bring you breaking news coverage on HIV and hepatitis C.
Look for reports from the HIVandHepatitis.com team and our content partners at NAM/Aidsmap.com starting Monday. Sign up for our email newsletter to get the latest headlines and follow us on Twitter @HIVandHepatitis.
CROI 2013: Adding Telaprevir Ups Acute Hepatitis C Cure Rate for HIV+ Men [VIDEO]
- Details
- Category: HIV/Hepatitis Coinfection
- Published on Friday, 08 March 2013 00:00
- Written by Gregory Fowler
Adding telaprevir (Incivek) to pegylated interferon/ribavirin for treating HIV positive men with acute sexually transmitted hepatitis C considerably shortens the duration of therapy and improves the likelihood of a cure, according to study findings presented this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
Liver Cancer Increasing among People with HIV/HCV Coinfection
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 15 February 2013 00:00
- Written by Liz Highleyman
Hepatocellular carcinoma (HCC) is a growing problem among HIV positive people coinfected with hepatitis C virus (HCV) in Spain, and it is often diagnosed at a late stage when it is difficult to treat, researchers reported in the January 1, 2013, issue of Clinical Infectious Diseases.
CROI 2013: French Studies Look at Telaprevir and Boceprevir for People with HIV/HCV Coinfection
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 06 March 2013 00:00
- Written by Liz Highleyman
Adding boceprevir or telaprevir to interferon-based therapy showed promising indications of efficacy and acceptable safety for difficult-to-treat HIV/HCV coinfected prior non-responders in a pair of French studies presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in this week in Atlanta.
Atazanavir (Reyataz) Label Update Adds Kidney Warning, Drug Interactions
- Details
- Category: HIV Treatment
- Published on Tuesday, 12 February 2013 00:00
- Written by FDA
Product label information for the HIV protease inhibitor atazanavir (brand name Reyataz) was recently revised to include new warnings about cholelithiasis or gall bladder stones and interstitial nephritis (a type of kidney inflammation), as well as interactions with several other medications, including the hepatitis C virus protease inhibitor boceprevir (Victrelis).
Coverage of the 2013 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Monday, 04 March 2013 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), March 3-6, 2013, in Atlanta.
Conference highlights include HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions and complications, treatment as prevention and PrEP, new treatments for hepatitis C, and HIV/HBV and HIV/HCV coinfection.
HIVandHepatitis.com CROI 2013 conference section
3/4/13
Coverage of 11th International Congress on Drug Therapy in HIV Infection
- Details
- Category: HIV Treatment
- Published on Saturday, 17 November 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 11th International Congress on Drug Therapy in HIV Infection (HIV11), November 11-15, 2012, Glasgow, Scotland.
Conference highlights include experimental antiretroviral drugs, ART strategies, manging side effects, HIV-related non-AIDS conditions, treatment as prevention and PrEP, HIV/HCV coinfection, and the search for a cure for HIV.
HIVandHepatitis.com HIV11 conference section
11/17/12
Web Design and Development by